Developing ELND005 for Agitation and Aggression in Alzheimer's Disease and TT401, in Partnership with Eli Lilly, for Diabetes

NEW YORK, NY / ACCESSWIRE / February 24, 2015 / LifeSci Capital, LLC, a research-driven investment bank with deep domain expertise in the life sciences sector, today announced that it has initiated coverage of Transition Therapeutics (NASDAQ:TTHI), which is developing a wholly-owned late-stage asset, ELND005, for the treatment of agitation & aggression neuropsychiatric symptoms in Alzheimer's disease and as a therapy for Down syndrome. The Company specializes in the development of promising assets that are licensed from large pharmaceutical companies, who retain the option to reacquire the assets for late-stage development and commercialization. Stemming from this strategy, Eli Lilly recently reacquired rights to develop the GLP-1 dual agonist TT401 for diabetes, and Transition is eligible for milestone and royalty payments.

Transition is developing its wholly-owned, late-stage asset ELND005 as a potential treatment for Alzheimer's disease (AD) and Down syndrome. This drug candidate, also known as scyllo-inositol, is an orally bioavailable small molecule that is in a 320 patient Phase II trial for agitation and aggression in mild to severe AD. TT401, also known as LY2944876, is a long-acting GLP-1 dual agonist being developed for glycemic control and weight reduction in patients with type 2 diabetes (T2D) and obesity. Lilly's early exercise of their option rights sends a strong message recognizing the value in TT401, and validates Transition's core business model. Eli Lilly is responsible for all future development and commercialization of TT401. If TT401 is approved, Transition is eligible to receive up to $240 million in milestone payments plus double-digit royalties on sales.

In a 33 page Initiation Report LifeSci Capital explains the expected development path for ELND005 as a treatment for agitation and aggression in Alzheimer's disease and other indications. The report highlights the market opportunity for ELND005 and also for TT401, as well as the existing market and competitive landscape.

Dr. Isaacson's full Initiation Report, including important disclosures, is available to download at no cost at the LifeSci Capital website, www.lifescicapital.com/equity-research/. In addition to this Initiation Report, LifeSci Capital intends to provide ongoing coverage and event-based research updates on Transition Therapeutics as developments occur.

The LifeSci Capital research team is led by Dr. Jerry Isaacson, an industry veteran with broad experience in biotechnology, having worked in both public and private biotech companies in areas ranging from medicinal chemistry and analytical chemistry to patents and investor/public relations. Dr. Isaacson holds a Bachelor of Arts degree in Chemistry from Harvard University and received his Ph.D. in Organic Chemistry from the University of California in San Diego.

Report Available here: www.lifescicapital.com/equity-research/transition/

About LifeSci Capital:

LifeSci Capital (Member: FINRA/SIPC) is a research-driven investment bank with deep domain expertise in the life sciences. Our service model as a boutique investment bank is unique in that we exclusively serve emerging life science companies that discover, develop, and commercialize innovative products. We view our clients as our partners, and we work closely with them to establish and execute their capital markets strategies. Our broadly-distributed equity research product is differentiated and provides a deep understanding of our clients' businesses and the opportunities they are addressing. To learn more about LifeSci Capital, visit the company's website, www.lifescicapital.com.

Analyst Contact:

Jerry Isaacson, Ph.D.
Phone: (646) 597-6991
Email: jisaacson@lifescicapital.com

SOURCE: LifeSci Capital, LLC